ECSP17038100A - Formas en estado sólido de pirrolidinonas heteroaromáticas fusionadas - Google Patents

Formas en estado sólido de pirrolidinonas heteroaromáticas fusionadas

Info

Publication number
ECSP17038100A
ECSP17038100A ECIEPI201738100A ECPI201738100A ECSP17038100A EC SP17038100 A ECSP17038100 A EC SP17038100A EC IEPI201738100 A ECIEPI201738100 A EC IEPI201738100A EC PI201738100 A ECPI201738100 A EC PI201738100A EC SP17038100 A ECSP17038100 A EC SP17038100A
Authority
EC
Ecuador
Prior art keywords
solid state
state forms
fused heteroaromatic
chemical entities
pyrrolidinones
Prior art date
Application number
ECIEPI201738100A
Other languages
English (en)
Spanish (es)
Inventor
Naoki Yoshikawa
Intellectual Property Gmbh Bayer
O'bryan Colin
Development And Quality E I R L Research
Takada Kenzo
Rongliang Chen
Automotiva S A Nakata
Gedeon Nyrt Richter
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55299676&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP17038100(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of ECSP17038100A publication Critical patent/ECSP17038100A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
ECIEPI201738100A 2014-12-18 2017-06-16 Formas en estado sólido de pirrolidinonas heteroaromáticas fusionadas ECSP17038100A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462093564P 2014-12-18 2014-12-18
US201562115223P 2015-02-12 2015-02-12
US201562180222P 2015-06-16 2015-06-16

Publications (1)

Publication Number Publication Date
ECSP17038100A true ECSP17038100A (es) 2017-12-01

Family

ID=55299676

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201738100A ECSP17038100A (es) 2014-12-18 2017-06-16 Formas en estado sólido de pirrolidinonas heteroaromáticas fusionadas

Country Status (29)

Country Link
US (3) US10676473B2 (enExample)
EP (2) EP3677582B1 (enExample)
JP (3) JP6778195B2 (enExample)
KR (1) KR102037502B1 (enExample)
CN (1) CN107108609B (enExample)
AU (1) AU2015365580B2 (enExample)
BR (1) BR112017013149B1 (enExample)
CA (1) CA2970864C (enExample)
CL (1) CL2017001561A1 (enExample)
CO (1) CO2017005910A2 (enExample)
CR (1) CR20170249A (enExample)
DK (1) DK3233857T3 (enExample)
DO (1) DOP2017000130A (enExample)
EA (1) EA032291B1 (enExample)
EC (1) ECSP17038100A (enExample)
ES (1) ES2788454T3 (enExample)
GE (2) GEAP201914545A (enExample)
IL (1) IL252941B (enExample)
MX (1) MX373586B (enExample)
MY (1) MY199935A (enExample)
NZ (1) NZ732371A (enExample)
PE (1) PE20171179A1 (enExample)
PH (1) PH12017501123A1 (enExample)
PL (1) PL3233857T3 (enExample)
SG (1) SG11201701911QA (enExample)
TN (1) TN2017000080A1 (enExample)
UA (1) UA120632C2 (enExample)
WO (1) WO2016097862A2 (enExample)
ZA (1) ZA201701800B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA032291B1 (ru) * 2014-12-18 2019-05-31 Такеда Фармасьютикал Компани Лимитед Твердые формы конденсированных гетероароматических пирролидинонов
EP3484466A1 (en) * 2016-07-13 2019-05-22 Takeda Pharmaceutical Company Limited Combination of spleen tyrosine kinase inhibitors and other therapeutic agents
CN111194319A (zh) 2017-10-19 2020-05-22 拜耳动物保健有限责任公司 稠合的杂芳族吡咯烷酮类化合物用于治疗和预防动物中的疾病的用途
WO2019088039A1 (en) 2017-10-30 2019-05-09 Takeda Pharmaceutical Company Limited Treatment of acute myeloid leukemia
KR102874906B1 (ko) * 2018-12-14 2025-10-21 치아타이 티안큉 파마수티컬 그룹 주식회사 Syk 억제제의 염 및 이의 결정형
JP2022519383A (ja) 2019-02-07 2022-03-23 ヤンセン バイオテツク,インコーポレーテツド ジヒドロオロト酸デヒドロゲナーゼ阻害剤
TW202104207A (zh) 2019-04-17 2021-02-01 美商健生生物科技公司 二氫乳清酸脫氫酶抑制劑
CN114630822B (zh) 2019-10-10 2024-10-01 詹森生物科技公司 联芳基二氢乳清酸脱氢酶抑制剂
UY38988A (es) 2019-12-19 2021-06-30 Janssen Pharmaceutica Nv Derivados espiráncos sustituidos de cadena lineal
WO2022074534A1 (en) 2020-10-05 2022-04-14 Janssen Biotech, Inc. Combinations of dihydroorotate dehydrogenase inhibitors and hypomethylating agents
WO2022127753A1 (zh) * 2020-12-18 2022-06-23 山东轩竹医药科技有限公司 稠环类AhR抑制剂
KR20240006638A (ko) 2021-05-11 2024-01-15 얀센 파마슈티카 엔브이 조합 요법
KR20240006631A (ko) 2021-05-11 2024-01-15 얀센 파마슈티카 엔브이 조합 요법
KR102539612B1 (ko) 2021-12-24 2023-06-02 엘에스일렉트릭(주) IP 기반 RAPIEnet을 지원하는 통신 디바이스 및 이를 포함하는 네트워크 시스템
WO2024114664A1 (en) 2022-11-30 2024-06-06 Janssen Pharmaceutica Nv Combinations comprising a menin-mll inhibitor and at least one other therapeutic agent
EP4626427A1 (en) 2022-11-30 2025-10-08 Janssen Pharmaceutica NV Combinations comprising a menin-mll inhibitor and a bcl-2 inhibitor

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1960372B1 (en) * 2005-12-15 2015-12-09 Rigel Pharmaceuticals, Inc. Kinase inhibitors and their uses
US8440689B2 (en) * 2009-12-23 2013-05-14 Takeda Pharmaceutical Company Limited Fused heteroaromatic pyrrolidinones
EP2723739B1 (en) * 2011-06-22 2016-08-24 Takeda Pharmaceutical Company Limited Substituted 6-aza-isoindolin-1-one derivatives
TW201625263A (zh) * 2014-09-24 2016-07-16 千禧製藥公司 利用PI3Kα抑制劑與紫杉烷之組合治療
EA032291B1 (ru) * 2014-12-18 2019-05-31 Такеда Фармасьютикал Компани Лимитед Твердые формы конденсированных гетероароматических пирролидинонов

Also Published As

Publication number Publication date
AU2015365580A1 (en) 2017-07-06
AU2015365580B2 (en) 2020-04-02
MX373586B (es) 2020-05-05
PL3233857T3 (pl) 2020-07-27
EP3677582B1 (en) 2023-01-25
IL252941B (en) 2020-11-30
US20230348461A1 (en) 2023-11-02
CA2970864A1 (en) 2016-06-23
GEAP201914545A (en) 2019-08-12
US10676473B2 (en) 2020-06-09
CL2017001561A1 (es) 2018-01-12
TN2017000080A1 (en) 2018-07-04
GEP20197050B (en) 2019-12-10
SG11201701911QA (en) 2017-04-27
DK3233857T3 (da) 2020-04-27
JP2022017477A (ja) 2022-01-25
HK1243406A1 (zh) 2018-07-13
EA201791369A1 (ru) 2017-10-31
KR102037502B1 (ko) 2019-10-28
US20160176869A1 (en) 2016-06-23
JP2017537969A (ja) 2017-12-21
KR20170095374A (ko) 2017-08-22
EP3233857A2 (en) 2017-10-25
US20200339573A1 (en) 2020-10-29
CR20170249A (es) 2017-09-25
EA032291B1 (ru) 2019-05-31
IL252941A0 (en) 2017-08-31
JP6778195B2 (ja) 2020-10-28
CO2017005910A2 (es) 2017-10-20
PH12017501123A1 (en) 2017-11-27
BR112017013149B1 (pt) 2022-10-11
US11352355B2 (en) 2022-06-07
WO2016097862A2 (en) 2016-06-23
UA120632C2 (uk) 2020-01-10
ZA201701800B (en) 2020-05-27
EP3233857B1 (en) 2020-03-11
DOP2017000130A (es) 2017-07-15
BR112017013149A2 (pt) 2018-04-10
CN107108609B (zh) 2020-02-18
WO2016097862A3 (en) 2016-08-11
MY199935A (en) 2023-11-29
NZ732371A (en) 2023-04-28
PE20171179A1 (es) 2017-08-22
EP3677582A1 (en) 2020-07-08
ES2788454T3 (es) 2020-10-21
CN107108609A (zh) 2017-08-29
MX2017007162A (es) 2017-08-28
CA2970864C (en) 2020-04-14
JP6974534B2 (ja) 2021-12-01
JP2020143081A (ja) 2020-09-10

Similar Documents

Publication Publication Date Title
ECSP17038100A (es) Formas en estado sólido de pirrolidinonas heteroaromáticas fusionadas
CL2019000942A1 (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret.
CL2019000941A1 (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret.
CO2018013803A2 (es) 1h-pirazolo[4,3-b]piridinas como inhibidores de pde1
MX2021006571A (es) Inhibidores de tirosina-cinasas.
EA202191301A1 (ru) СОСТАВ ТАБЛЕТОК 2-ФТОР-N-МЕТИЛ-4-[7-(ХИНОЛИН-6-ИЛМЕТИЛ)ИМИДАЗО[1,2-b][1,2,4]ТРИАЗИН-2-ИЛ]БЕНЗАМИДА
CO2017005784A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
SG10201807952PA (en) Jak1 inhibitors for the treatment of myelodysplastic syndromes
TW201613925A (en) Imidazopyrazines as LSD1 inhibitors
CL2015001985A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim.
MA49570A (fr) Composés bicycliques pyrazolo et triazolo utilisés en tant qu'inhibiteurs de kinase jak
EA201791133A1 (ru) Ингибиторы erk
SI3419978T1 (sl) Derivati pirazolo(1,5-A)pirazin-4-ila kot zaviralci z janusom povezane kinaze (JAK)
CL2016001840A1 (es) Compuestos derivados de pirimidinas fusionadas como inhibidores del complejo p97; composicion farmaceutica y uso en el tratamiento del cancer.
AR101905A1 (es) Compuestos bicíclicos
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
SI3227297T1 (sl) 4,6-substituirani-pirazolo(1,5-A)pirazini kot inhibitorji Janus kinaze
EP3551630A4 (en) IMIDAZO [1,5-A] PYRAZINE DERIVATIVES AS PI3KDELTA INHIBITORS
CO2017010621A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
MX375318B (es) Formas de dosificación y usos terapéuticos de l-4-cloro quinurenina..
MX2018014034A (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades.
CL2016003102A1 (es) 1h-1,8-naftiridin-2-onas como compuestos antiproliferativos.
ECSP18000097A (es) Inhibidores de tirosina-cinasas
UA96860U (xx) Похідні [1,2,4]триазоло[4,3-а]піразину